The new autoinjector has been approved for Cyltezo (adalimumab-adbm). Credit: National Cancer Institute on Unsplash.

Boehringer Ingelheim has secured approval from the US Food and Drug Administration (FDA) for its new autoinjector, the Cyltezo Pen.

The new autoinjector can be used to administer Cyltezo (adalimumab-adbm), which was approved by the FDA as an interchangeable biosimilar to its reference product Humira (adalimumab) in October 2021.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Cyltezo, which was initially approved as a pre-filled syringe, is intended for the treatment of multiple chronic inflammatory diseases.

Starting from 1 July 2023, the 40mg/0.8ml pre-filled Cyltezo Pen will be offered in two, four and six-pack options.

Boehringer Ingelheim biosimilar commercial lead and executive director Stephen Pagnotta said: “The FDA approval of the Cyltezo Pen is great news for patients living with chronic inflammatory diseases who may prefer administering the medication needed to manage their conditions via an autoinjector.

See Also:

“We’re excited to be able to offer the Cyltezo Pen as an additional option to patients at Cyltezo’s launch on 1 July.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The pen’s design is centred around the patient and incorporates a one-button system for activation in just three steps. It ensures complete visibility of the drug, while the needle is securely protected.

The Cyltezo Pen is certified by the Arthritis Foundation for its ease of use.

This month, Boehringer Ingelheim joined forces with Healthy.io to roll out an at-home testing programme, Minuteful Kidney, for patients at risk of chronic kidney disease (CKD).

Healthy.io’s Minuteful Kidney is claimed to be the first and only FDA-approved smartphone-based at-home ACR test for previously untested patients.